Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hyposkin

HypoSkin SIGNED

Unique breakthrough ex vivo human skin model to predict efficacy and toxicity of subcutaneous drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HypoSkin project word cloud

Explore the words cloud of the HypoSkin project. It provides you a very rough idea of what is the project "HypoSkin" about.

trials    money    700k    turnover    toulouse    global    drug    innovative    home    kit    vitro    times    founded    limits    regulatory    standardized    device    feasibility    models    french    worldwide    health    reduces    life    vivo    ready    medical    qualify    human    pharmaceuticals    reference    cheaper    pilot    sales    view    scientific    living    experiment    causing    clinical    provides    industrialise    sabatier    instrument    cagr    fat    care    deepen    animal    reliably    administration    sharp    save    off    inadequate    model    leads    ex    payed    absence    7    patient    innovation    world    biological    sharpen    permits    jobs    paul    2017    first    predict    route    national    issue    faster    risks    110    sme    subcutaneous    skin    university    local    parenteral    improves    center    security    disruptive    genoskin    hyposkin    1b    plans    replace    confirmed    company    attrition    effect    customers    88    quality    time    complete    2024    containing    spin    tissue    injection    accurate    decrease    34    2011    market    alternative    secure    biopsies    framework    companies   

Project "HypoSkin" data sheet

The following table provides information about the project.

Coordinator		 GENOSKIN SAS 

Organization address
address: CENTRE PIERRE POTIER, 1 PLACE PIERRE POTIER
city: TOULOUSE
postcode: 31100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.genoskin.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOSKIN SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Subcutaneous injection drug market is highly increasing (CAGR of 7%) and is view as a viable alternative route for parenteral drug administration because it enables at-home injection, improves quality of life and reduces health care costs. However, the absence of accurate biological model to predict the effect of drug injection in the subcutaneous tissue limits their development. That issue leads to 88% of drug attrition causing a loss of more than €1B per developed drug and a sharp decrease of patient security during clinical trials.

HypoSkin is the first and unique in vitro standardized and ready-to-use testing kit containing living ex vivo human skin biopsies with subcutaneous fat, allowing pharmaceuticals to highly reliably predict local human’s response to the injection of a drug or a medical device. This disruptive innovation permits Hyposkin’s customers to save time and money (10 times faster and 5 times cheaper than animal experiment, confirmed in the on-going payed pilot test) as well as secure the development of their products before clinical trials. HypoSkin will become worldwide reference method to replace inadequate animal testing currently used today.

HypoSkin model is developed by Genoskin an innovative French company, founded in 2011 as a spin-off of the French National Center for Scientific Research and the Paul Sabatier University in Toulouse. Genoskin provides other human-skin alternative models to pharmaceuticals companies all over the world leading to sales of €700K in 2017.

The SME Instrument project will allow the company to improve, qualify and industrialise HypoSkin. To accomplish this goal Genoskin will complete a feasibility study to further analyse risks and cost of scale-up, the European regulatory framework and will deepen and sharpen the global subcutaneous injection market. Genoskin plans to lead the European and global alternative method market with an estimated turnover of € 34 M by 2024, and 110 new European and worldwide jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More  

PRIVATETRACK (2019)

PRIVATETRACK: Privacy-friendly, low-power intelligent room occupancy detection and people counting.

Read More